LAWRENCE KWONG to Melanoma
This is a "connection" page, showing publications LAWRENCE KWONG has written about Melanoma.
Connection Strength
2.140
-
Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.
Score: 0.271
-
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
Score: 0.189
-
miRNAs, Melanoma and Microenvironment: An Intricate Network. Int J Mol Sci. 2017 Nov 07; 18(11).
Score: 0.185
-
Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Rep. 2017 05 16; 19(7):1304-1312.
Score: 0.179
-
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70.
Score: 0.154
-
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res. 2013 Oct 01; 19(19):5310-9.
Score: 0.139
-
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012 Oct; 18(10):1503-10.
Score: 0.130
-
The brothers RAF. Cell. 2010 Jan 22; 140(2):180-2.
Score: 0.108
-
Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol. 2007; 23:99-129.
Score: 0.087
-
Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma. J Invest Dermatol. 2023 09; 143(9):1779-1787.e1.
Score: 0.067
-
Calibration-free NGS quantitation of mutations below 0.01% VAF. Nat Commun. 2021 10 21; 12(1):6123.
Score: 0.061
-
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Res. 2021 10 15; 81(20):5230-5241.
Score: 0.060
-
High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci Rep. 2021 04 27; 11(1):9043.
Score: 0.059
-
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res. 2019 11 15; 25(22):6852-6867.
Score: 0.052
-
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 10 01; 24(19):4771-4784.
Score: 0.048
-
Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 2017 Apr 11; 8(15):25395-25417.
Score: 0.045
-
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clin Cancer Res. 2016 Dec 15; 22(24):6088-6098.
Score: 0.043
-
Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep. 2016 05 31; 15(9):2012-24.
Score: 0.042
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.041
-
Dual Roles of RNF2 in Melanoma Progression. Cancer Discov. 2015 Dec; 5(12):1314-27.
Score: 0.040
-
Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014 12 23; 7(357):ra121.
Score: 0.038
-
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286.
Score: 0.037
-
Integrative genome comparison of primary and metastatic melanomas. PLoS One. 2010 May 24; 5(5):e10770.
Score: 0.028
-
Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. Genome Biol. 2021 09 06; 22(1):227.
Score: 0.015
-
In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov. 2018 05; 8(5):568-581.
Score: 0.012
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.011